These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33825489)

  • 1. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Prikoszovich T; Marculescu R; Beitzke D; Wielandner A; Erben RG; Oberbauer R
    Circ Res; 2021 May; 128(11):1616-1625. PubMed ID: 33825489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
    Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
    Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.
    ; Shoji T; Inaba M; Fukagawa M; Ando R; Emoto M; Fujii H; Fujimori A; Fukui M; Hase H; Hashimoto T; Hirakata H; Honda H; Hosoya T; Ikari Y; Inaguma D; Inoue T; Isaka Y; Iseki K; Ishimura E; Itami N; Ito C; Kakuta T; Kawai T; Kawanishi H; Kobayashi S; Kumagai J; Maekawa K; Masakane I; Minakuchi J; Mitsuiki K; Mizuguchi T; Morimoto S; Murohara T; Nakatani T; Negi S; Nishi S; Nishikawa M; Ogawa T; Ohta K; Ohtake T; Okamura M; Okuno S; Shigematsu T; Sugimoto T; Suzuki M; Tahara H; Takemoto Y; Tanaka K; Tominaga Y; Tsubakihara Y; Tsujimoto Y; Tsuruya K; Ueda S; Watanabe Y; Yamagata K; Yamakawa T; Yano S; Yokoyama K; Yorioka N; Yoshiyama M; Nishizawa Y
    JAMA; 2018 Dec; 320(22):2325-2334. PubMed ID: 30535217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
    Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.
    Seeherunvong W; Abitbol CL; Chandar J; Rusconi P; Zilleruelo GE; Freundlich M
    Pediatr Nephrol; 2012 Nov; 27(11):2129-2136. PubMed ID: 22710695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
    Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Programmed approach to the treatment of secondary hyperparathyroidism in chronic renal disease].
    Samokhvalov NA; Maĭstrenko NA; Romashchenko PN
    Vestn Khir Im I I Grek; 2013; 172(2):43-6. PubMed ID: 24000678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study.
    Fortier C; Mac-Way F; De Serres SA; Marquis K; Douville P; Desmeules S; Larivière R; Agharazii M
    Am J Hypertens; 2014 Nov; 27(11):1346-54. PubMed ID: 24695980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study.
    Ivarsen P; Povlsen JV; Christensen KL
    Scand J Urol Nephrol; 2012 Oct; 46(5):381-8. PubMed ID: 22724916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
    Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of Parsabiv
    Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
    Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.